Overview Request Sample Pages Request Customization Download PDF
You are viewing: UK Transplant Diagnostics Market analysis
Part of: Transplant Diagnostics Market (Global)

The UK Transplant Diagnostics Market was valued at $1895.1 Million in 2026 and projected to reach to $2739.7 Million by 2031, representing a compound annual growth rate of 7.6%. The UK Transplant Diagnostics Market is poised for sustained growth as NHS trusts and private transplant centers increasingly prioritize advanced diagnostic technologies to improve transplant success rates and patient outcomes.

UK Transplant Diagnostics Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

UK Transplant Diagnostics Market Trends and Insights

  • This segment encompasses diagnostic testing infrastructure, immunological assessments, and organ compatibility evaluations that Hospitals & Transplant Centers rely upon to optimize transplant outcomes and reduce rejection rates.
  • Hospitals & Transplant Centers are increasingly adopting advanced diagnostic platforms to enhance pre- and post-transplant monitoring, driving consistent market expansion at a 7.6% compound annual growth rate. The growth trajectory for Hospitals & Transplant Centers reflects rising transplant volumes, heightened regulatory scrutiny around graft survival, and integration of molecular and genomic diagnostics into clinical protocols.
  • Hospitals & Transplant Centers are investing in next-generation sequencing, HLA typing, and donor-specific antibody detection to improve patient stratification and long-term allograft function.
  • Between 2026 and 2031, Hospitals & Transplant Centers will continue to be the dominant adopter of transplant diagnostic solutions, supported by expanding transplant programs and reimbursement frameworks that recognize the clinical and economic value of comprehensive diagnostic testing..

Key Market Statistics

  • CAGR (2026-2031) 7.6% CAGR
  • Market Size, 2026 ~USD 1895.1 Million
  • Forecast, 2031 ~USD 2739.7 Million
  • Country UK

UK Transplant Diagnostics Market Overview

UK Market Valuation :

The UK Transplant Diagnostics Market is valued at $1,895.1 million in 2026, demonstrating significant investment in transplant infrastructure and diagnostic capabilities across NHS trusts and private transplant centers.

Strong Growth Trajectory :

With a CAGR of 7.6% through 2031, the UK market is expanding faster than historical trends, driven by increased organ transplant volumes, advanced immunological testing adoption, and enhanced pre-transplant evaluation protocols.

NHS Modernization Impact :

NHS England's commitment to improving transplant outcomes and reducing organ rejection rates is accelerating demand for sophisticated diagnostic solutions, HLA typing, and real-time organ compatibility assessments.

Projected Market Expansion :

The market is forecast to reach $2,739.7 million by 2031, representing a $844.6 million increase, reflecting growing adoption of precision diagnostics and expanded transplant programs across UK healthcare facilities.

UK Transplant Diagnostics Market Dynamics

  • Rising organ donation awareness campaigns, coupled with regulatory support for transplant optimization, are driving investment in immunological assessments and HLA compatibility testing.
  • The market benefits from the UK's centralized transplant coordination system and emphasis on evidence-based clinical practices. Looking ahead to 2031, the market will be shaped by technological innovations in molecular diagnostics, integration of artificial intelligence in organ matching, and expansion of living donor transplant programs.
  • Increased funding for transplant infrastructure modernization and growing collaboration between NHS England and private diagnostic providers will further accelerate market penetration, positioning the UK as a leader in transplant diagnostic excellence within Europe..

Related Ecosystem

In Vitro Diagnostics

Top Technologies
  • Polymerase Chain Reaction (PCR)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Dna Microarrays
  • Assay Kits
  • Microarrays
Top Companies
  • ROCHE HOLDINGS AG
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation
  • Abbott Laboratories
  • Biomerieux s.a.

    Medical Devices

    Top Technologies
    • Polymerase Chain Reaction (PCR)
    • Magnetic Resonance Imaging (MRI)
    • Disposable Autoinjectors
    • Pulse Oximeters
    • Blood Pressure Monitors
    Top Companies
    • Medtronic plc
    • Abbott Laboratories
    • Stryker Corporation
    • Becton, Dickinson and Company
    • JOHNSON & JOHNSON

      Key Takeaways

      • Hospitals & Transplant Centers segment valued at $1,895.1M in 2026, expanding to $2,739.7M by 2031 at 7.6% CAGR
      • Hospitals & Transplant Centers are prioritizing molecular diagnostics and HLA typing to reduce graft rejection and improve long-term outcomes
      • Regulatory mandates and reimbursement policies are accelerating Hospitals & Transplant Centers' adoption of comprehensive pre- and post-transplant testing
      • Hospitals & Transplant Centers represent the largest end-user segment, driven by rising transplant volumes and clinical demand for precision diagnostics

      Transplant Diagnostics Market Report Scope

      Report Metric Details
      Base Year 2026
      Fastest Growing Segment NEXT-GENERATION SEQUENCING (NGS) (Application)
      Forecast Period 2026–2031
      Growth Rate CAGR of 7.8% from 2026 to 2031
      Largest Segment INDEPENDENT REFERENCE LABORATORIES (Type)
      Market Size Base Year (Billions) ~USD 5.59 (2026)
      Revenue Forecast (Billions) ~USD 8.14 (2031)
      Segments Covered Product & Service, Application, End User, Type, Transplant Type, Technology

      UK Transplant Diagnostics Market Report Segmentation

      6 segment dimensions are covered across the global market.

      By Product & Service

      • Instruments
      • Reagents & Consumables
      • Software & Services

      By Application

      • Blood Profiling
      • Diagnostic Applications
      • Histocompatibility Testing
      • Infectious Disease Testing
      • Post-Transplantation Diagnostics
      • Research Applications

      By End User

      • Hospitals & Surgical Centers
      • Hospitals & Transplant Centers
      • Independent Reference Laboratories
      • Research Laboratories & Academic Institutes

      By Type

      • Blood Profiling
      • Bone Marrow Transplantation
      • Heart
      • Heart Transplantation
      • Histocompatibility Testing
      • Infectious Disease Testing
      • Kidney
      • Kidney Transplantation
      • Liver
      • Liver Transplantation
      • Lung
      • Lung Transplantation
      • Next-Generation Sequencing (Ngs)
      • Ngs
      • Other Organs
      • Other Pcr-Based Molecular Assays
      • Other Sequencing Technologies
      • Other Sequencing-Based Molecular Assays
      • Other Solid Organ Transplantation
      • Pancreas
      • Pancreas Transplantation
      • Post-Transplantation Diagnostics
      • Pre-Transplantation Diagnostics
      • Real-Time Pcr
      • Sanger Sequencing
      • Sequence-Specific Oligonucleotide-Pcr (Sso-Pcr)
      • Sequence-Specific Primer-Pcr (Ssp-Pcr)
      • Soft Tissue Transplantation
      • Solid Organ Transplantation
      • Stem Cell Transplantation

      By Transplant Type

      • Bone Marrow Transplantation
      • Heart
      • Kidney
      • Liver
      • Lung
      • Other Organs
      • Pancreas
      • Soft Tissue Transplantation
      • Solid Organ Transplantation
      • Stem Cell Transplantation

      By Technology

      • Non-Molecular Assay Technologies
      • Pcr-Based Molecular Assays
      • Sequencing-Based Molecular Assays

      UK: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024–2031

      Segment20242025202620272028202920302031CAGR (%)
      HOSPITALS & TRANSPLANT CENTERS96.4102.1108.8116.2124.6133.9144.2155.77.4
      INDEPENDENT REFERENCE LABORATORIES167.7178.1190203.4218.4235.2253.7274.57.6
      RESEARCH LABORATORIES & ACADEMIC INSTITUTES16.617.618.719.921.322.924.626.57.2
      TOTAL280.7297.8317.4339.6364.3391.9422.4456.67.5

      Target Audience

      • NHS Trust Procurement Teams : Need comprehensive market data to evaluate diagnostic vendors, benchmark pricing against UK standards, and justify capital expenditure for transplant diagnostic infrastructure upgrades and modernization initiatives.
      • Transplant Center Medical Directors : Require insights into best-in-class diagnostic protocols, emerging technologies, and outcome benchmarks to optimize transplant success rates and implement evidence-based diagnostic strategies aligned with NHS standards.
      • In Vitro Diagnostics Manufacturers : Need UK market intelligence to assess commercial viability, identify unmet diagnostic needs, develop localized product offerings, and establish distribution partnerships with NHS-approved suppliers and private laboratories.
      • Healthcare Investment Firms : Seek detailed market forecasts, growth drivers, and competitive dynamics to evaluate investment opportunities in UK transplant diagnostic companies, technology platforms, and healthcare service providers.
      • Regulatory and Policy Advisors : Require market data to inform NHS policy recommendations, transplant program funding decisions, and regulatory frameworks that support diagnostic innovation and improved transplant outcomes across UK healthcare systems.

      Key Companies in the UK Transplant Diagnostics Market

      CompanyHQOwnershipStrongest segments
      KINDRED HEALTHCARE INC.United StatesPrivate CompanyLong-term acute care hospitals (LTACH) – drug-intensive episodes,Inpatient rehabilitation facilities – medically complex rehab,Contract rehabilitation services in third-party facilities,
      UNILABSSwitzerlandPrivate CompanyCore laboratory testing,Medical imaging,Pathology and centres of excellence,
      THERMO FISHER SCIENTIFIC INC.United StatesPublic CompanyLife Sciences Solutions,Analytical Instruments,Specialty Diagnostics,
      BIO-RAD LABORATORIES, INC.United StatesPublic CompanyClinical Diagnostics,Life Science,
      QIAGEN N.V.NetherlandsPublic CompanySample technology consumables and instruments,Molecular diagnostics (immune response, oncology, sexual and reproductive health),PCR and enzymes (research and applied testing),
      BIOMéRIEUXFrancePublic CompanyClinical microbiology (VITEK, BACT/ALERT, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS),Immunoassay and biomarkers (VIDAS, Hybiome CLIA),
      ILLUMINA, INC.United StatesPublic CompanySequencing instruments,Sequencing consumables (reagents, flow cells, library prep),Array-based instruments and consumables,
      BECTON, DICKINSON AND COMPANYUnited StatesPublic CompanyMedical Essentials (syringes, needles, vascular access, sharps, basic disposables),Connected Care (infusion therapy, medication management, pharmacy automation, informatics),BioPharma Systems (prefillable drug delivery, closed-system transfer devices),
      CAREDX, INC.United StatesPublic Companydd-cfDNA transplant surveillance (AlloSure Kidney/Heart/Lung, AlloSeq cfDNA, AlloHome),Gene expression and multimodal testing (AlloMap Heart, HeartCare, HistoMap Kidney, AlloHeme),HLA typing and transplant lab solutions (QTYPE, Olerup SSP, AlloSeq Tx, AlloSeq HCT, Allocell),
      DIASORIN S.P.A.ItalyPublic CompanyImmunodiagnostics – Infectious and Gastrointestinal Diseases,Immunodiagnostics – Endocrinology and Metabolic Disorders,Oncology and Tumor Markers,
      MERCK KGAAGermanyPublic CompanyLife Science (reagents, consumables, instruments, bioprocessing, CDMO),Healthcare (oncology, neurology & immunology, fertility, rare diseases),Electronics (semiconductor and display materials, specialty gases, equipment),
      HOLOGIC, INC.United StatesPrivate CompanyDiagnostics (Aptima, Panther, ThinPrep, fetal fibronectin),Breast Health (3D mammography, biopsy, localization, software),GYN Surgical (MyoSure, NovaSure, Fluent, Acessa, CoolSeal),
      EUROBIO SCIENTIFICFrancePublic CompanyInfectious disease & molecular biology (EBX, EurobioPlex, biosafety),Transplantation & immunology (AlloMap, GenDx, immunology products),Oncology diagnostics (EndoPredict, Prolaris),

      KINDRED HEALTHCARE INC.

      Kindred Healthcare Inc. is a large private healthcare services company founded in 1985 in the United States, employing 64,200 people. The company operates in the healthcare and medical services sector.

      UNILABS

      Unilabs is a private laboratory and diagnostics company founded in 1987 in Switzerland with 1,897 employees. The company offers clinical laboratory and diagnostic testing services.

      THERMO FISHER SCIENTIFIC INC.

      Thermo Fisher Scientific Inc. is a public multinational life sciences company founded in 1956 in the United States with 125,000 employees. The company provides laboratory equipment, reagents, and analytical instruments globally.

      BIO-RAD LABORATORIES, INC.

      Bio-Rad Laboratories, Inc. is a public life sciences and clinical diagnostics company founded in 1952 in the United States with 7,450 employees. The company manufactures and distributes products for the clinical laboratory and life sciences research markets.

      QIAGEN N.V.

      QIAGEN N.V. is a public molecular diagnostics and life sciences company founded in 1984 in the Netherlands with 5,500 employees. The company provides sample and assay technologies for molecular diagnostics and research.

      BIOMéRIEUX

      bioMérieux is a public in vitro diagnostics company founded in 1963 in France with 14,894 employees. The company specializes in microbiology and immunoassay diagnostic solutions.

      ILLUMINA, INC.

      Illumina, Inc. is a public genomics and life sciences company founded in 1998 in the United States with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.

      BECTON, DICKINSON AND COMPANY

      Becton, Dickinson and Company is a public medical technology company founded in 1897 in the United States with 72,000 employees. The company manufactures and sells medical devices, laboratory equipment, and diagnostic products worldwide.

      CAREDX, INC.

      CareDx, Inc. is a public molecular diagnostics company founded in 1998 in the United States with 763 employees. The company develops and offers diagnostic solutions for transplant patients.

      DIASORIN S.P.A.

      DiaSorin S.p.A. is a public in vitro diagnostics company founded in 1968 in Italy with 3,242 employees. The company manufactures and distributes diagnostic products for clinical laboratories.

      MERCK KGAA

      Merck KGaA is a public pharmaceutical, chemical, and life sciences company founded in 1668 in Germany with 59,077 employees. The company operates globally in healthcare, life sciences, and performance materials sectors.

      HOLOGIC, INC.

      Hologic, Inc. is a private medical technology company founded in 1985 in the United States with 7,070 employees. The company develops and manufactures diagnostic and medical imaging products.

      EUROBIO SCIENTIFIC

      Eurobio Scientific is a public in vitro diagnostics company founded in 1997 in France with 343 employees. The company specializes in diagnostic reagents and laboratory solutions.

      Reasons to Buy this Report

      • UK-Specific Market Sizing : Obtain precise valuation data for the UK market ($1,895.1M in 2026) with granular forecasts through 2031, enabling accurate budget allocation and investment planning for UK-based healthcare providers and diagnostic manufacturers.
      • NHS Procurement Intelligence : Understand NHS England's procurement patterns, tender requirements, and reimbursement frameworks specific to transplant diagnostics, critical for suppliers seeking to win contracts with major UK transplant centers and hospital networks.
      • Competitive Landscape Analysis : Identify leading diagnostic providers, emerging competitors, and market consolidation trends within the UK transplant diagnostics sector, enabling strategic positioning and partnership opportunities.
      • Growth Driver Identification : Analyze UK-specific factors driving the 7.6% CAGR, including regulatory changes, transplant volume increases, and technology adoption rates, to inform product development and market entry strategies.
      • End-User Segmentation : Access detailed insights into UK hospitals and transplant centers' diagnostic needs, budget cycles, and technology preferences, enabling targeted sales strategies and customized solution development.

      Frequently asked questions

      What is the market size for Hospitals & Transplant Centers in 2026?

      Hospitals & Transplant Centers segment is valued at $1,895.1 million in 2026.

      What is the projected market size for Hospitals & Transplant Centers by 2031?

      Hospitals & Transplant Centers segment is forecast to reach $2,739.7 million by 2031.

      What is the CAGR for Hospitals & Transplant Centers?

      Hospitals & Transplant Centers are growing at a compound annual growth rate of 7.6% from 2026 to 2031.

      Why are Hospitals & Transplant Centers investing in transplant diagnostics?

      Hospitals & Transplant Centers invest in transplant diagnostics to optimize graft survival, reduce rejection rates, and improve patient outcomes through precision immunological and molecular testing.

      What diagnostic technologies are Hospitals & Transplant Centers adopting?

      Hospitals & Transplant Centers are adopting next-generation sequencing, HLA typing, donor-specific antibody detection, and molecular genomic platforms to enhance pre- and post-transplant monitoring.

      RESEARCH METHODOLOGY

      The objective of this study is to analyze the key market dynamics, including drivers, opportunities, constraints, challenges, and strategies employed by key players. We will track developments within companies, such as acquisitions, product launches, expansions, agreements, and partnerships, to assess the competitive landscape of the transplant diagnostics market. This analysis will evaluate market players across various parameters within the broader categories of business and product strategy.
      To estimate the market size, both top-down and bottom-up approaches were utilized. The market breakdown and data triangulation were employed to determine the sizes of segments and subsegments.
      The four steps involved in estimating the market size are:

      Secondary Research

      In the secondary research process, various secondary sources such as annual reports, press releases & investor presentations of companies, white papers, certified publications, articles by recognized authors, gold-standard & silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva) were referred to identify and collect information for this study.

      Primary Research

      In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries, as well as preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations across all segments of this industry’s value chain. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts, C-level executives at key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and to assess prospects.
      The following is a breakdown of the primary respondents:

      Transplant Diagnostics Market Size, and Share

      Note 1: Other designations include sales, marketing, and product managers.
      Note 2: Companies are classified into tiers based on their total revenues. As of 2025, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = <USD 10 million.

      COMPANY NAME

      DESIGNATION

      Thermo Fisher Scientific Inc. (US)

      Sales Manager

      F. Hoffmann-La Roche AG (Switzerland)

      Product Manager

      To know about the assumptions considered for the study, download the pdf brochure

      Market Size Estimation

      Both top-down and bottom-up approaches were used to estimate and validate the total size of the transplant diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

      • The key players in the industry have been identified through extensive secondary research.
      • The revenues generated by leading players operating in the transplant diagnostics market have been determined through primary and secondary research.
      • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

      The research methodology used to estimate the market size includes the following:

      Transplant Diagnostics Market : Top-Down and Bottom-Up Approach

      Transplant Diagnostics Market Top Down and Bottom Up Approach

      Data Triangulation

      After arriving at the overall market size using the process described above, the total market was split into several segments and subsegments. To complete the overall market engineering process and obtain the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

      Market Definition

      Transplant diagnostic procedures are used to determine donor-recipient compatibility to avoid the risk of immune rejection in a recipient. These procedures are adopted for donor-recipient cross-matching, subject profiling, genotyping, and other related diagnostic tests. Advanced genomic techniques (such as PCR and NGS) are increasingly used in transplant diagnostic procedures, alongside serological and other conventional techniques for immunocompatibility testing (such as antibody-antigen reactions and leucocyte assays).

      Key Stakeholders

      • Transplant diagnostic product manufacturing companies
      • Healthcare service providers (including hospitals, transplant centers, and blood transfusion centers)
      • Blood, tissue, and stem cell banks
      • Government organizations
      • Independent associations & regulatory authorities
      • R&D companies
      • Independent reference laboratories
      • Diagnostic laboratories
      • Clinical research organizations

      Report Objectives

      • To define, segment, and forecast the transplant diagnostics market by product & service, technology, application, type, end user, and region
      • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
      • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market 
      • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
      • To forecast the size of the market segments with respect to five regions: North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa.
      • To profile key players and comprehensively analyze their product portfolios, market positions, and core competencies
      • To benchmark players within the market using the proprietary Company Evaluation Matrix framework, which analyzes market players on various parameters within the broad categories of business and product excellence
      • To study the impact of AI on the market, along with the macroeconomic outlook for each region

      Available customizations:

      MarketsandMarkets offers the following customizations for this market report.

      Product Analysis

      • Product matrix, which provides a detailed comparison of the product portfolio of each company in the transplant diagnostics market

      Company Profiles

      • Additional five company profiles of players operating in the transplant diagnostics market.

      Country Information

      • Additional country-level analysis of the transplant diagnostics market

      Get the Full Transplant Diagnostics Market Report

      Full forecast, segment splits, and company analysis for all Transplant Diagnostics Market.

      Download Sample Pages Buy Report

      METHODOLOGY

      Need a Tailored Report?

      Customize this report to your needs

      Get 10% FREE Customization

      Customize This Report
      Fact checked
      Cite this Research
      DMCA.com Protection Status